The introduction of Retatrutide ZPHC, at a strength of 120mg, is generating considerable interest within the healthcare community. This innovative dual GIP and GLP-1 receptor medication appears to deliver significant improvements in body reduction compared to current therapies. Early research trials have indicated substantial reductions in body fat